It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Different mutations of the OTOF gene, encoding for otoferlin protein expressed in the cochlear inner hair cells, induces a form of deafness that is the major cause of nonsyndromic recessive auditory neuropathy spectrum disorder in humans. We report the generation of the first large animal model of OTOF mutations using the CRISPR system associated with different Cas9 components (mRNA or protein) assisted by single strand oligodeoxynucleotides (ssODN) to induce homology-directed repair (HDR). Zygote microinjection was performed with two sgRNA targeting exon 5 and 6 associated to Cas9 mRNA or protein (RNP) at different concentrations in a mix with an ssODN template targeting HDR in exon 5 containing two STOP sequences. A total of 73 lambs were born, 13 showing indel mutations (17.8%), 8 of which (61.5%) had knock-in mutations by HDR. Higher concentrations of Cas9-RNP induced targeted mutations more effectively, but negatively affected embryo survival and pregnancy rate. This study reports by the first time the generation of OTOF disrupted sheep, which may allow better understanding and development of new therapies for human deafness related to genetic disorders. These results support the use of CRISPR/Cas system assisted by ssODN as an effective tool for gene editing in livestock.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Instituto de Reproducción Animal Uruguay, Fundación IRAUy, Montevideo, Uruguay
2 Unidad de Animales Transgénicos y de Experimentación (UATE), Institut Pasteur de Montevideo, Montevideo, Uruguay (GRID:grid.418532.9)
3 Inserm, Centre de Recherche en Transplantation et Immunologie, UMR 1064, Nantes, France (GRID:grid.462425.3) (ISNI:0000 0004 0449 1513); Transgenesis Rat ImmunoPhenomic facility (TRIP), Nantes, France (GRID:grid.462425.3)
4 Inserm, Centre de Recherche en Transplantation et Immunologie, UMR 1064, Nantes, France (GRID:grid.462425.3) (ISNI:0000 0004 0449 1513); GenoCellEdit facility, Nantes, France (GRID:grid.462425.3)
5 Inserm, Centre de Recherche en Transplantation et Immunologie, UMR 1064, Nantes, France (GRID:grid.462425.3) (ISNI:0000 0004 0449 1513); Transgenesis Rat ImmunoPhenomic facility (TRIP), Nantes, France (GRID:grid.462425.3); GenoCellEdit facility, Nantes, France (GRID:grid.462425.3)